Atopic dermatitis, also known as eczema, is a skin condition that can cause extreme discomfort, social stigmatization, and isolation for those who suffer from it. The FDA recently approved a new drug from Eli Lilly called EBGLYSS, which targets the action of a cytokine believed to be the primary driver behind the condition. This drug is now approved for use in adults and children 12 years or older who have moderate-to-severe atopic dermatitis. The condition is characterized by itchy skin, most commonly located on the arms or behind the knees, which can lead to red, swollen, cracked, and weeping skin that may crust over and scale as it heals.
The primary drivers of atopic dermatitis are IL-4 and IL-13, with IL-13 considered the dominant force in the condition. Lilly’s EBGLYSS inhibits production of IL-13, making it a valuable addition to the arsenal of dermatologists treating this condition. Treatment with EBGLYSS involves an initial startup dose followed by injections every 2 weeks until week 16, and then monthly injections thereafter. The drug was found to be effective in the ADvocate trials, with 38% of participants achieving clear or nearly clear skin at 16 weeks into the trial, and 77% maintaining those results after 1 year of monthly dosing.
Side effects of EBGLYSS may include eye and eyelid inflammation, injection site reactions, and shingles. Despite these potential side effects, the drug has been shown to significantly improve the quality of life for those suffering from atopic dermatitis. The constant itching associated with the condition can be debilitating, affecting sleep, work, and social interactions. However, successful treatment with biologics like EBGLYSS can lead to a dramatic improvement in symptoms, allowing patients to sleep through the night, feel more confident, and enhance their overall quality of life.
Dr. Hannah Kopleman, a dermatologist, highlighted the transformative effect that effective treatments like EBGLYSS can have on patients with atopic dermatitis. She shared the story of a patient who experienced constant itching, painful flareups, and frequent infections before receiving treatment. After starting a regimen that included biologics like EBGLYSS, the patient’s symptoms improved significantly, allowing them to sleep better, feel more confident, and improve their overall quality of life. With the FDA’s approval of drugs like EBGLYSS, dermatologists are now able to offer more effective and tailored treatments that can make a real difference in managing atopic dermatitis and restoring patients’ confidence and quality of life.
